Supporting oncology professionals through education

The content on this site is intended for healthcare professionals only

Conferences

ecancer travels so that you don't have to. Explore the latest conference coverage in global oncology and find out where we are going next.

WCGC 14

27 - 30 Jun 2012

Gastric cancer in Japan

Dr Takeshi Sano - National Cancer Centre Hospital, Tokyo, Japan

Gastric cancer in Japan ( Dr Takeshi Sano - National Cancer Centre Hospital, Tokyo, Japan )

Genetic signatures for colon cancer

Prof Pierre Laurent-Puig - University of Paris, France

Genetic signatures for colon cancer ( Prof Pierre Laurent-Puig - University of Paris, France )

An improving outlook for liver cancer patients

Dr Graeme Poston - University Hospital Aintree, Liverpool, UK

An improving outlook for liver cancer patients ( Dr Graeme Poston - University Hospital Aintree, Liverpool, UK )

Colorectal cancer in the elderly

Dr Demetris Papamichael - BO Cyprus Oncology Centre, Nicosia, Cyprus

Colorectal cancer in the elderly ( Dr Demetris Papamichael - BO Cyprus Oncology Centre, Nicosia, Cyprus )

The EUREKA Initiative

Prof Cornelius van de Velde - Leiden University Medical Center, Netherlands

The EUREKA Initiative ( Prof Cornelius van de Velde - Leiden University Medical Center, Netherlands )

Neuroendocrine tumours of the pancreas

Prof Aurel Perren - University of Bern, Switzerland

Neuroendocrine tumours of the pancreas ( Prof Aurel Perren - University of Bern, Switzerland )

Prevention best ‘treatment’ for colon cancer

Prof Nadir Arber – Integrated Cancer Prevention Center, Tel Aviv Medical Center, Israel

Prevention best ‘treatment’ for colon cancer ( Prof Nadir Arber – Integrated Cancer Prevention Center, Tel Aviv Medical Center, Israel )

Bevacizumab benefits beyond progression in TML study subgroups

Dr Thierry André – Hôpital Saint Antoine, Paris, France

Bevacizumab benefits beyond progression in TML study subgroups ( Dr Thierry André – Hôpital Saint Antoine, Paris, France )

Pharmacodynamic endpoints need to be included in GI trials

Prof Fortunato Ciardiello – Seconda Università degli Studi di Napoli, Italy

Pharmacodynamic endpoints need to be included in GI trials ( Prof Fortunato Ciardiello – Seconda Università degli Studi di Napoli, Italy )

Exploring new targets in GI cancer

Prof Josep Tabernero – Vall d’Hebron Institute of Oncology (VHIO), Barcelona, Spain

Exploring new targets in GI cancer ( Prof Josep Tabernero – Vall d’Hebron Institute of Oncology (VHIO), Barcelona, Spain )

Unravelling mechanisms of resistance to targeted drugs

Prof Salvatore Siena – Niguarda Ca’ Granda Hospital, Milan, Italy

Unravelling mechanisms of resistance to targeted drugs ( Prof Salvatore Siena – Niguarda Ca’ Granda Hospital, Milan, Italy )

CORRECT study data prompts US FDA priority review

Prof Alberto Sobrero – Ospedale San Martino, Genova, Italy

CORRECT study data prompts US FDA priority review ( Prof Alberto Sobrero – Ospedale San Martino, Genova, Italy )

Anti-angiogenic trials; key highlights of the 14th WCGC

Prof Eric Van Cutsem – University Hospital Leuven, Gasthuisberg, Belgium

Anti-angiogenic trials; key highlights of the 14th WCGC ( Prof Eric Van Cutsem – University Hospital Leuven, Gasthuisberg, Belgium )

Perifosine disappoints in refractory mCRC

Dr Johanna Bendell – Sarah Cannon Research Institute, Nashville, USA

$Perifosine disappoints in refractory mCRC ( Dr Johanna Bendell – Sarah Cannon Research Institute, Nashville, USA )$

Screening and specialist nurses central to patient care

Jola Gore-Booth – EuropaColon, France / UK

Screening and specialist nurses central to patient care ( Jola Gore-Booth – EuropaColon, France / UK )

Tivantinib first drug to have overall survival benefit as second-line hepatocellular carcinoma treatment

Dr Camillo Porta – Fondazione IRCCS Policlinico Universitario San Matteo, Pavia, Italy

Tivantinib first drug to have overall survival benefit as second-line hepatocellular carcinoma treatment ( Dr Camillo Porta – Fondazione IRCCS Policlinico Universitario San Matteo, Pavia, Italy )

Adjuvant cetuximab disappoints again in mCRC

Prof Michel Ducreux – Institut Gustave Roussy, Villejuif, France

Adjuvant cetuximab disappoints again in mCRC ( Prof Michel Ducreux – Institut Gustave Roussy, Villejuif, France )

Young Voices United against CRC

Dr Dino Tarabar – Military Medical Academy, Belgrade, Serbia

Young Voices United against CRC ( Dr Dino Tarabar – Military Medical Academy, Belgrade, Serbia )

Advances in radiotherapy for rectal cancer

Dr Karin Haustermans – University Hospital Leuven, Belgium

Advances in radiotherapy for rectal cancer ( Dr Karin Haustermans – University Hospital Leuven, Belgium )

Important to support young medical oncologists’ research

Prof Roberto Labianca – Riuniti Hospital, Bergamo, Italy

Important to support young medical oncologists’ research ( Prof Roberto Labianca – Riuniti Hospital, Bergamo, Italy )

More from ecancer